Lucy Scientific Discovery Inc. LSDIF
- Market cap
- $900.0K
- P/E
- 0.0×
Follow LSDIF
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 1.75 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 40.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 2 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | — | 35.71% |
Gross Margin
|
|||
| — | — | — | — | — | — | (4) | (5) | (6) | (9) |
EBT
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | (128,407.14%) |
EBT Margin
|
|||
| — | — | — | — | — | — | (3) | (5) | (6) | (9) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (0.19) | (0.29) | (6.80) | (7.10) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (0.03) | (0.09) | (2.81) | (3.36) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | (0.04) | (0.21) |
Capex/Sh
|
|||
| — | — | — | — | — | — | (0.03) | (0.09) | (2.85) | (3.57) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | (0.27) | (0.40) | (5.55) | 3.68 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 16 | 16 | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 3.12 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | — | (3.38) |
EV/FCF
|
|||
| — | — | — | — | — | — | 0 | (1) | (2) | (4) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | 0 | (1) | (2) | (5) |
FCF
|
|||
| — | — | — | — | — | — | (4) | (4) | (4) | 1 |
Working Cap'
|
|||
| — | — | — | — | — | — | 1 | 2 | 3 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | 1 | 2 | 3 | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | (4) | (6) | (5) | 5 |
Sh' Equity
|
|||
| — | — | — | — | — | — | 0.00% | (166.57%) | (114.98%) | (134.06%) |
ROA
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | (83.12%) |
ROIC
|
|||
| — | — | — | — | — | — | 0.00% | 88.39% | 105.19% | 18,140.26% |
ROE
|
|||
Lucy Scientific Discovery Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PTPI Petros Pharmaceuticals, Inc. | $1.0M | 0.0× | Compare |
| NEPTF Neptune Wellness Solutions Inc. | $1.6M | 0.0× | Compare |
| IMCC IM Cannabis Corp. | $2.0M | 0.0× | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AKAN Akanda Corp. | $2.4M | — | Compare |
| PRFX PainReform Ltd. | $3.0M | 0.0× | Compare |
| RDHL Redhill Biopharma Ltd. | $3.2M | 0.0× | Compare |
| SBFM Sunshine Biopharma, Inc. | $3.3M | 0.0× | Compare |
Lucy Scientific Discovery Inc. (LSDIF) key facts
- Lucy Scientific Discovery Inc. (LSDIF) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
- Lucy Scientific Discovery Inc.’s revenue for fiscal 2023 (year ended June 2023) was $7,000.00.
- Lucy Scientific Discovery Inc. reported a net loss of $9.0 million, or a loss of $7.10 per share, for fiscal 2023.
- Return on equity was 18,140.3% and debt-to-equity 0.00.
Lucy Scientific Discovery Inc. (LSDIF) Latest News
28 May
Lucy Scientific Discovery Inc. received Nasdaq notification of non-compliance with listing rule 5250(c)(1) due to delinquent filing of quarterly report. The potential impact on the company's compliance with Nasdaq rules may moderately affect its financial performance and competitive positioning.
26 May
Agrify converts debt to equity, Glass House seeks Canadian funding, TILT reports stable sales; Awakn advances with Catalent, Lucy faces challenges with NASDAQ compliance. Lucy Scientific Discovery Inc. (LSDI) facing mounting challenges and NASDAQ compliance pressure could significantly alter its trajectory and investor sentiment.
16 Feb
Lucy Scientific Discovery Inc. announces 1-for-10 reverse stock split to comply with Nasdaq minimum bid requirement. The reverse stock split may have a moderately noticeable influence on the company's financial performance and competitive positioning.
18 Oct
Lucy Scientific Discovery Inc. (LSDI) is pioneering alternative mental health treatments, including psychedelics and herbal remedies, to address the limitations of traditional SSRIs. Legislative changes and investor interest are driving growth in the industry. The article highlights significant legislative changes, investor interest, and potential market growth in the alternative mental health treatments sector, which could have a profound impact on LSDI's future and market performance.
26 Sep
Lucy Scientific Discovery (NASDAQ: LSDI) acquires High Times IP for growth opportunities. Acquisition of High Times IP is expected to significantly alter LSDI's trajectory and revenue streams.
20 Sep
Lucy Scientific Discovery (NASDAQ: LSDI) leverages M&A for synergistic growth in psychotropic businesses. The article highlights LSDI's strategic M&A approach to amplify shareholder value in the psychotropic industry.
15 Sep
Lucy Scientific Discovery acquires BlueSky Wellness Inc., expanding its psychotropic product catalog with brands generating over $20 million in revenue. The acquisition of BlueSky Wellness Inc. and its brands is a significant move that is expected to alter LSDI's trajectory and market performance.
Lucy Scientific Discovery acquires BlueSky Wellness, adding psychotropic products to its catalog. Acquisition of BlueSky Wellness and High Times assets expected to add significant revenue and EBITDA, positioning LSDI for substantial growth.
13 Sep
Lucy Scientific Discovery Inc. (LSDI) to acquire BlueSky Wellness in all-stock transaction. Acquisition of BlueSky Wellness is a significant strategic move that could alter LSDI's trajectory and market sentiment.
12 Sep
Lucy Scientific Discovery Inc. acquires BlueSky Wellness Inc., expanding its psychotropic product portfolio and global reach. The acquisition of BlueSky Wellness Inc. and its brands is expected to significantly impact Lucy Scientific Discovery Inc.'s future revenue and market performance.
Lucy Scientific Discovery Inc. acquires BlueSky Wellness Inc., expanding into the global wellness category with psychotropic products. The acquisition of BlueSky Wellness Inc. and its portfolio of brands is expected to significantly impact Lucy Scientific Discovery Inc.'s future growth and market performance.
8 Sep
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) announces editorial placement in FinancialNewsMedia, highlighting growth in global cannabis market. The article discusses LSDI's strategic positioning in the projected $51B global cannabis market, indicating significant impact on the company's future and market performance.
Lucy Scientific Discovery acquires High Times intellectual property. The acquisition of High Times IP is a significant move that can drive high margin revenue and grow market presence globally.
7 Sep
High Times Holding Corp. to go public via deal with Lucy Scientific Discovery Inc. in all-stock transaction. The deal is a significant strategic move that enables High Times to become publicly traded and expands investment opportunities for over 40,000 stockholders.
High Times Holdings Corp. exchanges core IP assets for 19.9% stake in Lucy Scientific Discovery (NASDAQ: LSDI) plus milestone payments. The acquisition of High Times IP is expected to significantly impact Lucy Scientific Discovery Inc.'s future revenue and growth potential.
Lucy Scientific acquires High Times IP and licensing agreements in all-stock deal. The acquisition of High Times IP and licensing agreements is a significant move that could alter LSDI's trajectory and market sentiment.
20 Jul
Pasithea Therapeutics Special Committee rejects unsolicited bid from Lucy Scientific Discovery, Inc. The rejection of the bid by Pasithea Therapeutics could significantly impact the future and market performance of Lucy Scientific Discovery, Inc.
14 Jul
Lucy Scientific Discovery (NASDAQ:LSDI) had a cash runway of around 13 months as of March 2023 with increasing cash burn. The article highlights the potential impact of cash burn on the company's future financial performance.
13 Jul
Richard Nanula appointed as CEO of Lucy Scientific Discovery Inc. (LSDI) after senior roles at Disney, Amgen, Starwood. The appointment of a CEO with experience from major companies like Disney and Amgen is likely to have a significant impact on LSDI's future and market performance.
Richard Nanula appointed as new CEO of Lucy Scientific Discovery Inc. The appointment of a Fortune 500 veteran as CEO is a significant strategic move that could fundamentally alter the company's trajectory and market performance.
11 Jul
Lucy Scientific Discovery Inc. launches new sleep aid product Twilight, containing Amanita and Reishi mushrooms. The launch of a new product with potential to address a widespread issue like sleep disorders could significantly impact the company's future performance and market position.
5 Jul
Lucy Scientific Discovery Inc. completes acquisition of Wesana Health assets and forms Lucy Discoveries Holdings for future research and development. The acquisition of innovative mental health therapeutics and formation of a new entity signal significant strategic moves that could reshape the company's trajectory and competitive position.